Table 1.
Baseline characteristics of the two groups of patients
| Index | Control group n=42 | Observation group n=45 | Statistic value | P |
|---|---|---|---|---|
| Age | 63.45±11.52 | 63.67±12.17 | 0.086 | 0.931 |
| Gender: Male Female | 24/18 | 22/23 | ||
| BMI | 19.32±2.71 | 19.18±3.26 | 0.217 | 0.829 |
| ECOG score | ||||
| 0~1 | 33 (78.57) | 37 (82.22) | ||
| 2~4 | 9 (21.43) | 8 (17.78) | 0.427 | 0.670 |
| Primary tumor site | ||||
| colon | 29 (69.05) | 30 (66.67) | ||
| rectum | 13 (30.95) | 15 (33.33) | 0.056 | 0.812 |
| Pathological type | ||||
| Adenocarcinoma | 38 (90.48) | 40 (88.89) | ||
| Mucinous adenocarcinoma | 3 (7.14) | 3 (6.67) | ||
| Villous adenoma canceration | 1 (2.38) | 2 (4.44) | 0.282 | 0.869 |
| TNM stage | ||||
| III | 11 (26.19) | 10 (22.22) | ||
| IV | 31 (73.81) | 35 (77.78) | 0.430 | 0.667 |
| Number of metastases | ||||
| 1 | 22 (52.38) | 21 (46.67) | ||
| 2 | 14 (33.33) | 16 (35.56) | ||
| 3 | 5 (11.90) | 6 (13.38) | ||
| 4 | 1 (2.38) | 2 (4.44) | 0.594 | 0.552 |
| Metastasis site | ||||
| Localized liver metastasis | 17 (40.48) | 15 (33.33) | ||
| Non-restricted liver metastasis | 15 (35.71) | 19 (42.22) | ||
| Non-liver metastasis | 10 (23.81) | 11 (24.44) | 0.540 | 0.763 |
| Chemotherapy | ||||
| Irinotecan Based | 23 (54.76) | 25 (55.56) | ||
| Oxaliplatin-based | 14 (33.33) | 17 (37.78) | ||
| Irinotecan + oxaliplatin based | 3 (7.14) | 2 (4.44) | ||
| fluoropyrimidine alone | 2 (4.76) | 1 (2.22) | 0.804 | 0.848 |
| Chemotherapy cycle | 5.26±2.75 | 5.71±2.93 | 0.737 | 0.463 |